由于早期识别和更先进的治疗，癌症死亡率正在下降。然而，许多不利的副作用，包括长期、持久的炎症和免疫功能下降，通常与抗癌治疗同时存在，并导致生活质量普遍下降。标准化综合治疗的改进和各种侵袭性肿瘤的早期识别仍然是癌症研究的主要目标。癌症患者的肿瘤标志物是具有临床意义的肿瘤相关蛋白。尽管常规使用多种肿瘤标志物，但它们并不总能提供可靠的诊断信息。血清细胞因子是肿瘤分期、预后和治疗反应的有前途的标志物。事实上，目前有几种细胞因子被认为是多种癌症的潜在生物标志物。事实上，有人提出，对循环细胞因子和癌症特有的生物标志物的研究可以增强和加速癌症的诊断和预测，特别是通过需要最少甚至无侵袭的血液样本。本综述的目的是严格审查相关的主要研究文献，以阐明一些已确定的血清细胞因子作为肿瘤疾病前瞻性治疗靶点的作用和重要性。版权所有© Bentham Science Publishers；如有任何疑问，请发送电子邮件至 epub@benthamscience.net。

The death rate from cancer is declining as a result of earlier identification and more advanced treatments. Nevertheless, a number of unfavourable adverse effects, including prolonged, long-lasting inflammation and reduced immune function, usually coexist with anti-cancer therapies and lead to a general decline in quality of life. Improvements in standardized comprehensive therapy and early identification of a variety of aggressive tumors remain the main objectives of cancer research. Tumor markers in those with cancer are tumor-associated proteins that are clinically significant. Even while several tumor markers are routinely used, they don't always provide reliable diagnostic information. Serum cytokines are promising markers of tumor stage, prognosis, and responsiveness to therapy. In fact, several cytokines are currently proposed as potential biomarkers in a variety of cancers. It has actually been proposed that the study of circulatory cytokines together with biomarkers that are particular to cancer can enhance and accelerate cancer diagnosis and prediction, particularly via blood samples that require minimal to the absence of invasion. The purpose of this review was to critically examine relevant primary research literature in order to elucidate the role and importance of a few identified serum cytokines as prospective therapeutic targets in oncological diseases.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.